Showing results (991-1000 of 1,137) with videos related to

Sort By:
Pageof 114
Nature Genetics|September 19, 2018
Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetesHarm-Jan Westra, Marta Martínez-Bonet, Suna Onengut-Gumuscu, et al.
American Journal of Human Genetics|March 25, 2014
Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneityBuhm Han, Dorothée Diogo, Steve Eyre, et al.
Nature Communications|March 8, 2024
Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell developmentTaehyeung Kim, Marta Martínez-Bonet, Qiang Wang, et al.
JCO Precision Oncology|April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort StudyRuben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
JCI Insight|May 13, 2020
Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritisAndrea Fava, Jill Buyon, Chandra Mohan, et al.
Nature Immunology|May 25, 2021
Multimodally profiling memory T cells from a tuberculosis cohort identifies cell state associations with demographics, environment and diseaseAparna Nathan, Jessica I Beynor, Yuriy Baglaenko, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 7, 2015
Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid ArthritisChikashi Terao, Noriyuki Yamakawa, Koichiro Yano, et al.
The Journal of Rheumatology|April 2, 2022
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) MeetingCarmel Stober, Iain B McInnes, Soumya Raychaudhuri, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
British Journal of Haematology|March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaTaiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Pageof 114